newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

  • Ascentage Pharma reported first-half 2026 revenue of US$44.5 million, a 29% year-over-year increase driven by higher product sales.
  • The company appointed Dr. Faical Miyara as Chief Business Officer & Mr. James Ziegler as Chief Commercial Officer to strengthen executive leadership.
  • Nine registrational Phase III clinical trials are currently active globally, with four cleared by the FDA & EMA.
  • Olverembatinib formulary coverage expanded to 879 sites (including 394 hospitals) as of June 30, 2026, representing a 12% overall increase.
  • Enrollment continues for POLARIS-1, POLARIS-2, & POLARIS-3 trials evaluating Olverembatinib in Ph+ ALL, CML, & SDH-deficient GIST.
  • Lisaftoclax formulary coverage reached 415 sites (including 60 hospitals) as of June 30, 2026, with ongoing enrollment in GLORA, GLORA-2, GLORA-3, & GLORA-4 trials.
  • APG-3288 received FDA IND clearance in January 2026 & China CDE clearance in February 2026 for global Phase I studies in B-cell malignancies.
  • Selling & distribution expenses rose 64.3% to US$33.4 million due to increased marketing investment for Lisaftoclax.
  • Research & development expenses increased 32.0% to US$102.8 million reflecting higher costs for global clinical trials.
  • The company reported a net loss of US$120.4 million for the six months ended June 30, 2026, with cash balances decreasing to US$279.4 million.
  • Investor webcasts for the H1 2026 results are scheduled for August 20, 2026, in both Mandarin & English.